Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research organization located in the Netherlands. Through the acquisition, CrownBio will expand its portfolio of in vitro services, integrating OcellO\u2019s expertise in high content imaging alongside CrownBio\u2019s in vitro and in vivo screens and immunotherapy assessment services. Financial terms are not being disclosed.<\/p>\n\n\n\n
\u201cCrownBio and OcellO believe that the key to improving clinical research success is to utilize more patient-relevant models and assays that can generate reliable efficacy data as early as possible in the drug development process,\u201d said Armin Spura, PhD, Chief Executive Officer of CrownBio. \u201cThis acquisition brings together the complementary strengths of our two companies, enhancing our in vitro services portfolio and offering customers the ability to better evaluate multiple drug combinations and targets, across a wider range of tumor and cancer types, with improved predictability and clinical relevance moving from in vitro to in vivo phases of drug discovery.\u201d<\/p>\n\n\n\n
The acquisition establishes CrownBio as the only global source licensed to offer customers specialized Hubrecht Organoid Technology (HUB) for drug development programs. Under the terms of the agreement, Leo Price, PhD, OcellO\u2019s Chief Executive Officer and Chief Scientific Officer, will join CrownBio as Senior Vice President, In Vitro, to lead the Company\u2019s in vitro business in the US and Europe.<\/p>\n\n\n\n